MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial.
暂无分享,去创建一个
Mitchell D Schnall | Elizabeth A Morris | Etta D Pisano | Helga S Marques | Mark A Rosen | Savannah C Partridge | Constance D Lehman | L. Esserman | N. Hylton | J. Scheel | C. Lehman | E. Pisano | P. Weatherall | S. Partridge | E. Morris | M. Rosen | M. Schnall | W. Bernreuter | G. Newstead | Sandra M. Polin | H. Marques | Nola M Hylton | Paul T Weatherall | Laura J Esserman | Eunhee Kim | Sandra M Polin | John R Scheel | Wanda K Bernreuter | Gillian M Newstead | Eunhee Kim
[1] Anna L. Brown,et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] John Kornak,et al. Real-Time Measurement of Functional Tumor Volume by MRI to Assess Treatment Response in Breast Cancer Neoadjuvant Clinical Trials: Validation of the Aegis SER Software Platform. , 2014, Translational oncology.
[3] Samuel J. Magny,et al. Breast Imaging Reporting and Data System , 2020, Definitions.
[4] A. Stuckey,et al. ACR Appropriateness Criteria® Monitoring Response to Neoadjuvant Systemic Therapy for Breast Cancer. , 2017, Journal of the American College of Radiology : JACR.
[5] M. Dewhirst,et al. Accuracy of MRI in the detection of residual breast cancer after neoadjuvant chemotherapy. , 2003, AJR. American journal of roentgenology.
[6] Nola Hylton,et al. Clinically Meaningful Tumor Reduction Rates Vary by Prechemotherapy MRI Phenotype and Tumor Subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2013, Annals of Surgical Oncology.
[7] G J Metzger,et al. MRI vs. histologic measurement of breast cancer following chemotherapy: Comparison with x‐ray mammography and palpation , 2001, Journal of magnetic resonance imaging : JMRI.
[8] G. Hortobagyi,et al. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] Christos Hatzis,et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] F. Akiyama,et al. MR and US imaging for breast cancer patients who underwent conservation surgery after neoadjuvant chemotherapy: comparison of triple negative breast cancer and other intrinsic subtypes , 2011, Breast cancer.
[11] A. Soran,et al. MRI Staging After Neoadjuvant Chemotherapy for Breast Cancer: Does Tumor Biology Affect Accuracy? , 2011, Annals of Surgical Oncology.
[12] J. Ahn,et al. Accuracy of MRI for estimating residual tumor size after neoadjuvant chemotherapy in locally advanced breast cancer: Relation to response patterns on MRI , 2007, Acta oncologica.
[13] L. Esserman,et al. Locally advanced breast cancer: MR imaging for prediction of response to neoadjuvant chemotherapy--results from ACRIN 6657/I-SPY TRIAL. , 2012, Radiology.
[14] G. Hortobagyi,et al. Factors predictive of outcome in patients with breast cancer refractory to neoadjuvant chemotherapy. , 2001, Cancer journal.
[15] N. Hylton,et al. Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer , 2013, Cancer.
[16] D. Noh,et al. Magnetic resonance imaging evaluation of residual ductal carcinoma in situ following preoperative chemotherapy in breast cancer patients. , 2012, European journal of radiology.
[17] Rebecca S Lewis,et al. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. , 2004, Radiology.
[18] Martine Meunier,et al. Role of dynamic magnetic resonance imaging in the evaluation of tumor response to preoperative concurrent radiochemotherapy for large breast cancers: a prospective phase II study. , 2007, International journal of radiation oncology, biology, physics.
[19] Hon J. Yu,et al. Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. , 2011, Radiology.
[20] B. Dunn,et al. The Role of Tamoxifen in Breast Cancer Prevention , 2001, Annals of the New York Academy of Sciences.
[21] S. Lipsitz,et al. Does MRI predict pathologic tumor response in women with breast cancer undergoing preoperative chemotherapy? , 2007, Journal of surgical oncology.
[22] Yeon-Hee Park,et al. Analysis of Factors that Influence the Accuracy of Magnetic Resonance Imaging for Predicting Response after Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer , 2013, Annals of Surgical Oncology.
[24] L. Irwig,et al. Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis , 2015, BMC Cancer.
[25] Nola Hylton,et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] D. Berry,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[27] S. Vinnicombe,et al. Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer , 2008, British Journal of Cancer.
[28] M. Su. Magnetic Resonance Imaging as a Predictor of Pathologic Response in Patients Treated With Neoadjuvant Systemic Treatment for Operable Breast Cancer: Translational Breast Cancer Research Consortium Trial 017 , 2013 .
[29] M. Dieci,et al. Magnetic Resonance Imaging and Ultrasonography in Predicting Infiltrating Residual Disease after Preoperative Chemotherapy in Stage II–III Breast Cancer , 2011, Annals of Surgical Oncology.
[30] J. Gornbein,et al. Accuracy of clinical evaluation of locally advanced breast cancer in patients receiving neoadjuvant chemotherapy , 2009, Cancer.
[31] E. DeLong,et al. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.
[32] Dianne Georgian-Smith,et al. Prospective comparison of mammography, sonography, and MRI in patients undergoing neoadjuvant chemotherapy for palpable breast cancer. , 2005, AJR. American journal of roentgenology.
[33] G. Bonadonna,et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[34] B. Fitzgerald,et al. Optimal assessment of residual disease after neo‐adjuvant therapy for locally advanced and inflammatory breast cancer—clinical examination, mammography, or magnetic resonance imaging? , 2010, Journal of surgical oncology.
[35] C. Zuiani,et al. Locally advanced breast cancer: comparison of mammography, sonography and MR imaging in evaluation of residual disease in women receiving neoadjuvant chemotherapy , 2004, European Radiology.
[36] Ying Lu,et al. Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. , 2002, AJR. American journal of roentgenology.
[37] S. Ciatto,et al. Meta-analysis of agreement between MRI and pathologic breast tumour size after neoadjuvant chemotherapy , 2013, British Journal of Cancer.
[38] S. Harms,et al. Technical Report of the International Working Group on Breast MRI , 1999, Journal of magnetic resonance imaging : JMRI.
[39] Marc E. Lenburg,et al. Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657) , 2011, Breast Cancer Research and Treatment.
[40] D. Noh,et al. Age and HER2 expression status affect MRI accuracy in predicting residual tumor extent after neo-adjuvant systemic treatment. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.